Effect of Hydroxyurea on Mortality and Morbidity in Adult Sickle Cell Anemia: Risks and Benefits Up to 9 Years of Treatment
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Context: Hydroxyurea increases levels of fetal hemoglobin (HbF) and decreases morbidity from vaso-occlusive complications in patients with sickle cell anemia (SCA). High HbF levels reduce morbidity and mortality. Objective: To determine whether hydroxyurea attenuates mortality in patients with SCA. Design: Long-term observational follow-up study of mortality in patients with SCA who originally participated in the randomized, double-blind, placebo-controlled Multicenter Study of Hydroxyurea in Sickle Cell Anemia (MSH), conducted in 1992-1995, to determine if hydroxyurea reduces vaso-occlusive events. In the MSH Patients' Follow-up, conducted in 1996-2001, patients could continue, stop, or start hydroxyurea. Data were collected during the trial and in the follow-up period. Setting: Inpatients and outpatients in 21 sickle cell referral centers in the United States and Canada. Patients: Two-hundred ninety-nine adult patients with frequent painful episodes enrolled in the follow-up. Follow-up data through May 2001 were complete for 233 patients. Intervention: In the MSH, patients were randomly assigned to receive hydroxyurea (n = 152) or placebo (n = 147). Main Outcome Measure: Mortality, HbF levels, painful episodes, acute chest syndrome, and blood cell counts. The randomized trial was not designed to detect specified differences in mortality. Results: Seventy-five of the original 299 patients died, 28% from pulmonary disease. Patients with reticulocyte counts less than 250 000/mm 3 and hemoglobin levels lower than 9 g/dL had increased mortality (P = .002). Cumulative mortality at 9 years was 28% when HbF levels were lower than 0.5 g/dL after the trial was completed compared with 15% when HbF levels were 0.5 g/dL or higher (P = .03 ). Individuals who had acute chest syndrome during the trial had 32% mortality compared with 18% of individuals without acute chest syndrome (P = .02). Patients with 3 or more painful episodes per year during the trial had 27% mortality compared with 17% of patients with less frequent episodes (P = .06). Taking hydroxyurea was associated with a 40% reduction in mortality (P = .04) in this observational follow-up with self-selected treatment. There were 3 cases of cancer, 1 fatal. Conclusions: Adult patients taking hydroxyurea for frequent painful sickle cell episodes appear to have reduced mortality after 9 of years follow-up. Survival was related to HbF levels and frequency of vaso-occlusive events. Whether indications for hydroxyurea treatment should be expanded is unknown.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Longitudinal data analysis using generalized linear models
LIANG, K.-Y., & ZEGER, S. L. (1986) · Biometrika · doi:10.1093/biomet/73.1.13 · Cited by 18,550
(2005) · Technometrics · doi:10.1198/tech.2005.s303 · Cited by 17,923
Bain, L. J. (1967) · Technometrics · doi:10.1080/00401706.1967.10490452 · Cited by 3,407
Mortality in sickle cell disease. Life expectancy and risk factors for early death
Platt, O. S., Brambilla, D. J., Rosse, W. F., Milner, P. F., Castro, O., Steinberg, M. H., & Klug, P. P. (1994) · New England Journal of Medicine · doi:10.1056/nejm199406093302303 · Cited by 3,320 · cited 12×
“Objective To determine whether hydroxyurea attenuates mortality in patients with SCA.”
BackgroundResultInfluentialSelf-citationEffect of hydroxyurea on the frequency of painful crises in sickle cell anemia
Charache, S., Terrin, M. L., Moore, R. D., Dover, G. J., Barton, F. B., Eckert, S. V., McMahon, R. P., & Bonds, D. R. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505183322001 · Cited by 2,340 · cited 13×
“A single 2-year value was computed by averaging available data during the final 18 to 24 months of study treatment.(2) Levels of HbF were expressed as absolute levels of HbF in g/dL (HbF [g/dL]=HbF [%] hemoglobin concentration [g/dL]) because no biological mechanism of HbF production exists that would regulate HbF as…”
BackgroundMethodInfluentialSelf-citationThe Analysis of Cross-Classified Categorical Data
Drane, J. W. (1979) · Technometrics · doi:10.1080/00401706.1979.10489789 · Cited by 1,941
Cerebrovascular accidents in sickle cell disease: rates and risk factors.
(1998) · PubMed · doi:10.1182/blood.v91.1.288 · Cited by 1,694
Self-citationPain in Sickle Cell Disease: Rates and Risk Factors
Platt, O. S., Thorington, B. D., Brambilla, D. J., Milner, P. F., Rosse, W. F., Vichinsky, E., & Kinney, T. R. (1991) · New England Journal of Medicine · doi:10.1056/nejm199107043250103 · Cited by 1,546
Self-citationCauses and Outcomes of the Acute Chest Syndrome in Sickle Cell Disease
Vichinsky, E. P., Neumayr, L. D., Earles, A. N., Williams, R., Lennette, E. T., Dean, D., Nickerson, B., Orringer, E., McKie, V., Bellevue, R., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006223422502 · Cited by 1,234
Self-citationThe Analysis of Cross-Classified Categorical Data.
Gokhale, D. V., & Fienberg, S. E. (1979) · Journal of the American Statistical Association · doi:10.2307/2286999 · Cited by 828
Castro, O., Brambilla, D., Thorington, B., Reindorf, C., Scott, R., Gillette, P., Vera, J., & Levy, P. (1994) · Blood · doi:10.1182/blood.v84.2.643.643 · Cited by 808
Self-citationAcute Chest Syndrome in Sickle Cell Disease: Clinical Presentation and Course
Vichinsky, E. P., Styles, L. A., Colangelo, L. H., Wright, E. C., Castro, O., Nickerson, B., & Disease, T. C. S. O. S. C. (1997) · Blood · doi:10.1182/blood.v89.5.1787 · Cited by 573
Self-citationFetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea
Steinberg, M. H., Lu, Z.-H., Barton, F. B., Terrin, M. L., Charache, S., Dover, G. J., & Hydroxyurea, T. M. S. O. (1997) · Blood · doi:10.1182/blood.v89.3.1078 · Cited by 407 · cited 2×
“This combination of findings suggests that these patients had more severe disease and perhaps reduced marrow reserve and that, as a result, they were unable to tolerate sufficient hydroxyurea treatment to increase HbF levels.(6) Anemia and reticulocytopenia may also be indications of early renal failure that is associ…”
BackgroundMethodSelf-citationSterkers, Y., Preudhomme, C., Laı̈, J.-L., Demory, J.-L., Caulier, M.-T., Wattel, E., Bordessoule, D., Bauters, F., & Fenaux, P. (1998) · Blood · doi:10.1182/blood.v91.2.616 · Cited by 372
Chronic Renal Failure in Sickle Cell Disease: Risk Factors, Clinical Course, and Mortality
Powars, D. R., Elliott-Mills, D. D., Chan, L., Niland, J., Hiti, A. L., Opas, L. M., & Johnson, C. (1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-115-8-614 · Cited by 360
Hydroxyurea and Sickle Cell Anemia Clinical Utility of a Myelosuppressive “Switching” Agent
Charache, S., Barton, F. B., Moore, R. D., Terrin, M. L., Steinberg, M. H., Dover, G. J., Ballas, S. K., McMahon, R. P., Castro, O., & Orringer, E. P. (1996) · Medicine · doi:10.1097/00005792-199611000-00002 · Cited by 335
Self-citationNajean, Y., & Rain, J.-D. (1997) · Blood · doi:10.1182/blood.v90.9.3370 · Cited by 297
Design of the multicenter study of hydroxyurea in sickle cell anemia
Charache, S., Terrin, M. L., Moore, R. D., Dover, G. J., McMahon, R. P., Barton, F. B., Waclawiw, M., & Eckert, S. V. (1995) · Controlled Clinical Trials · doi:10.1016/s0197-2456(95)00098-4 · Cited by 273
Self-citationFive years of experience with hydroxyurea in children and young adults with sickle cell disease
Ferster, A., Tahriri, P., Vermylen, C., Sturbois, G., Corazza, F., Fondu, P., Devalck, C., Dresse, M. F., Feremans, W., Hunninck, K., et al. (2001) · Blood · doi:10.1182/blood.v97.11.3628 · Cited by 220
A multiparameter analysis of sickle erythrocytes in patients undergoing hydroxyurea therapy
Bridges, K., Barabino, G., Brugnara, C., Cho, M., Christoph, G., Dover, G., Ewenstein, B., Golan, D., Guttmann, C., Hofrichter, J., et al. (1996) · Blood · doi:10.1182/blood.v88.12.4701.bloodjournal88124701 · Cited by 184 · cited 1×
“Besides HbF, proposed mediators of the clinical effectiveness of hydroxyurea include reductions in adherent reticulocytes that may help initiate vasoocclusion and in leukocytes that might release proinflammatory cytokines.(3,17) Neutrophil counts have been associated with mortality in other diseases besides sickle cel…”
BackgroundSelf-citationNajean, Y., & Rain, J. (1997) · Blood · doi:10.1182/blood.v89.7.2319 · Cited by 149
Kostis, J. B., Turkevich, D., & Sharp, J. (1984) · The American Journal of Cardiology · doi:10.1016/0002-9149(84)90624-6 · Cited by 129
Nand, S., Stock, W., Godwin, J., & Fisher, S. G. (1996) · American Journal of Hematology · doi:10.1002/(sici)1096-8652(199605)52:1<42::aid-ajh7>3.0.co;2-6 · Cited by 113
American Journal of Hematology
Zaja, F. F., FANIN, R., Barcellini, W., Cantoni, S., Carpenedo, M., Caparrotti, G., Carrai, V., Renzo, N. D., Santoro, C., Nicola, M. D., et al. (2006) · American Journal of Hematology · doi:10.1002/(issn)1096-8652 · Cited by 107
Subarachnoid hemorrhage in sickle-cell disease
Anson, J. A., Koshy, M., Ferguson, L., & Crowell, R. M. (1991) · Journal of Neurosurgery · doi:10.3171/jns.1991.75.4.0552 · Cited by 78
Ballas, S. K., Marcolina, M. J., Dover, G. J., Barton, F. B., & the Investigators of the Multicenter Study of Hydroxyurea Sickle Cell Anemia (1999) · British Journal of Haematology · doi:10.1046/j.1365-2141.1999.01339.x · Cited by 71
Self-citationCellular effects of hydroxyurea in Hb SC disease
Steinberg, M. H., Nagel, R. L., & Brugnara, C. (1997) · British Journal of Haematology · doi:10.1046/j.1365-2141.1997.3173132.x · Cited by 62
Self-citationLiozon, É., Brigaudeau, C., Trimoreau, F., Desangles, F., Fermeaux, V., Praloran, V., & Bordessoule, D. (1997) · Hematology and Cell Therapy · doi:10.1007/s00282-997-0011-x · Cited by 51
Acute Leukemia in a Patient with Sickle-Cell Anemia Treated with Hydroxyurea
Wilson, S. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-133-11-200012050-00029 · Cited by 48
Predictors of sudden cardiac death.
FRIEDMAN, G. D., Klatsky, A. L., & Ab, S. (1975) · PubMed · Cited by 48
Is Hydroxyurea Leukemogenic in Essential Thrombocythemia?
Tefferi, A. (1998) · Blood · doi:10.1182/blood.v92.4.1459 · Cited by 21
Are we underestimating the leukemogenic risk of hydroxyurea
Al‐Jam'a, A. H., Al-Dabbous, I. A., Al-Khatti, A. A., & Esan, F. G. (2002) · Saudi Medical Journal · doi:10.15537/1658-3175.1889 · Cited by 19
Cited by
Rees, D. C., Williams, T. N., & Gladwin, M. T. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61029-x · Cited by 2,504
Management of Sickle Cell Disease: Summary of the 2014 Evidence-Based Report by Expert Panel Members
Yawn, B. P., Buchanan, G. R., Afenyi-Annan, A. N., Ballas, S. K., Hassell, K. L., James, A. H., Jordan, L., Lanzkron, S. M., Lottenberg, R., Savage, W. J., et al. (2014) · JAMA · doi:10.1001/jama.2014.10517 · Cited by 1,599
Self-citationPopulation Estimates of Sickle Cell Disease in the U.S.
Hassell, K. L. (2010) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2009.12.022 · Cited by 1,211
Rund, D., & Rachmilewitz, E. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050436 · Cited by 939
Crizanlizumab for the prevention of pain crises in sickle cell disease.
Ataga, K. I., Kutlar, A., Kanter, J., Liles, D., Cancado, R., Friedrisch, J., Guthrie, T. H., Knight-Madden, J., Alvarez, O. A., Gordeuk, V. R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611770 · Cited by 914
Self-citation
Metadata
- Authors
- Steinberg, M. H., Barton, F., Castro, O., Pegelow, C. H., Ballas, S. K., Kutlar, A., Orringer, E., Bellevue, R., Olivieri, N., Eckman, J., Varma, M., Ramirez, G., Adler, B., Smith, W., Carlos, T., Ataga, K., DeCastro, L., Bigelow, C., Saunthararajah, Y., Telfer, M., Vichinsky, E., Claster, S., Shurin, S., Bridges, K., Waclawiw, M., Bonds, D., & Terrin, M.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2003-04-02
- Volume
- 289
- Issue
- 13
- Pages
- 1645
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2147182596
- Cited by
- 931
- References
- 34
- FWCI
- 19.13
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.